Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: Prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

Breast Cancer Research and Treatment

Volumn 126, Issue 1, 2011, Pages 109-117

  Noske, A ^a,b   Loibl, S ^c   Darb Esfahani, S ^b   Roller, M ^c   Kronenwett, R ^d   Muller B M ^b   Steffen, J ^c   Von Toerne, C ^d   Wirtz, R ^d   Baumann, I ^e   Hoffmann, G ^f   Heinrich, G ^g   Grasshoff, S T ^g   Ulmer, H U ^h   Denkert, C ^b   Von Minckwitz, G ^c,i  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c GERMAN BREAST GROUP   (Germany)

^d Siemens Healthcare Diagnostics   (Germany)

^e Hospital Sindelfingen Böblingen   (Germany)

^f ST JOSEFS HOSPITAL   (Germany)

^g Medical Office of Gynaecology   (Germany)

^h Klinikum Karlsruhe   (Germany)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Breast cancer; HER2; Kinetic RT PCR; Neoadjuvant therapy; Pathological complete response

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 79151470854     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1316-y     Document Type: Article

References (34)

1. H Yaziji AM Gown 2004 Accuracy and precision in her2/neu testing in breast cancer: are we there yet? Hum Pathol 35 143 146 10.1016/j.humpath.2004. 01.002 14991529 (Pubitemid 38240894)
2. MF Press DJ Slamon KJ Flom J Park JY Zhou L Bernstein 2002 Evaluation of her-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20 3095 3105 1:CAS:528:DC%2BD38XmtVCrtLk%3D 12118023 (Pubitemid 34791099)
3. A Lebeau D Deimling C Kaltz A Sendelhofert A Iff B Luthardt M Untch U Lohrs 2001 Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization J Clin Oncol 19 354 363 1:CAS:528:DC%2BD3MXhtVekt78%3D 11208826 (Pubitemid 32112846)
4. TA Thomson MM Hayes JJ Spinelli E Hilland C Sawrenko D Phillips B Dupuis RL Parker 2001 Her-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization Mod Pathol 14 1079 1086 1:STN:280:DC%2BD3MnltlarsA%3D%3D 10.1038/modpathol.3880440 11706067 (Pubitemid 33063199)
5. AM Gown 2008 Current issues in ER and HER2 testing by IHC in breast cancer Mod Pathol 21 Suppl 2 8 15 10.1038/modpathol.2008.34 (Pubitemid 351592775)
6. S Paik C Kim N Wolmark 2008 Her2 status and benefit from adjuvant trastuzumab in breast cancer N Engl J Med 358 1409 1411 1:CAS:528: DC%2BD1cXjvFCrsLw%3D 10.1056/NEJMc0801440 18367751 (Pubitemid 351468442)
7. AK Koutras KT Kalogeras MA Dimopoulos RM Wirtz U Dafni E Briasoulis D Pectasides H Gogas C Christodoulou G Aravantinos G Zografos E Timotheadou P Papakostas H Linardou E Razis T Economopoulos HP Kalofonos G Fountzilas 2008 Evaluation of the prognostic and predictive value of her family mRNA expression in high-risk early breast cancer: a hellenic cooperative oncology group (HECOG) study Br J Cancer 99 1775 1785 1:CAS:528:DC%2BD1cXhsVajtbrI 10.1038/sj.bjc. 6604769 18985033
8. K Bohmann G Hennig U Rogel C Poremba BM Mueller P Fritz S Stoerkel KL Schaefer 2009 RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods Clin Chem 55 1719 1727 1:CAS:528:DC%2BD1MXhtVynt77E 10.1373/clinchem. 2008.122572 19617290
9. G von Minckwitz S Kummel P Vogel C Hanusch H Eidtmann J Hilfrich B Gerber J Huober SD Costa C Jackisch S Loibl K Mehta M Kaufmann 2008 Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study J Natl Cancer Inst 100 552 562 10.1093/jnci/djn089
10. G von Minckwitz S Kummel P Vogel C Hanusch H Eidtmann J Hilfrich B Gerber J Huober SD Costa C Jackisch S Loibl K Mehta M Kaufmann 2008 Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial J Natl Cancer Inst 100 542 551 10.1093/jnci/djn085
11. J Huober G von Minckwitz C Denkert H Tesch E Weiss DM Zahm A Belau F Khandan M Hauschild C Thomssen B Hogel S Darb-Esfahani K Mehta S Loibl 2010 Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study Breast Cancer Res Treat 124 133 140 1:CAS:528:DC%2BC3cXht1elsLjK 10.1007/s10549-010-1103-9 20697801
12. DF Hayes S Ethier ME Lippman 2006 New guidelines for reporting of tumor marker studies in breast cancer research and treatment: remark Breast Cancer Res Treat 100 237 238 10.1007/s10549-006-9253-5 16773436 (Pubitemid 44631926)
13. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 Reporting recommendations for tumor marker prognostic studies (remark) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
14. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
15. S Darb-Esfahani S Loibl BM Muller M Roller C Denkert M Komor K Schluns JU Blohmer J Budczies B Gerber A Noske A du Bois W Weichert C Jackisch M Dietel K Richter M Kaufmann G von Minckwitz 2009 Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy Breast Cancer Res 11 R69 10.1186/bcr2363 19758440
16. Müller BM (2009) Quantitative determination of predictive cancer biomarkers in formalin-fixed, paraffin-embedded tissue using a new fully automated method for RNA isolation. J Clin Oncol 27 (suppl, abstr 11032)
17. AA Iverson C Gillett P Cane CD Santini TM Vess L Kam-Morgan A Wang M Eisenberg CM Rowland JJ Hessling SE Broder JJ Sninsky A Tutt S Anderson SY Chang 2009 A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens J Mol Diagn 11 117 130 1:CAS:528:DC%2BD1MXjs12qs7g%3D 10.2353/jmoldx.2009.080070 19225135
18. C Ginestier E Charafe-Jauffret F Penault-Llorca J Geneix J Adelaide M Chaffanet MJ Mozziconacci J Hassoun P Viens D Birnbaum J Jacquemier 2004 Comparative multi-methodological measurement of ERBB2 status in breast cancer J Pathol 202 286 298 1:CAS:528:DC%2BD2cXislejsLk%3D 10.1002/path.1523 14991893 (Pubitemid 38325237)
19. U Vinatzer B Dampier B Streubel M Pacher MJ Seewald C Stratowa K Kaserer M Schreiber 2005 Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-pcr as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization Clin Cancer Res 11 8348 8357 1:CAS:528:DC%2BD2MXht1KjsrnP 10.1158/1078-0432.CCR-05-0841 16322295 (Pubitemid 41746947)
20. M Kaufmann GN Hortobagyi A Goldhirsch S Scholl A Makris P Valagussa JU Blohmer W Eiermann R Jackesz W Jonat A Lebeau S Loibl W Miller S Seeber V Semiglazov R Smith R Souchon V Stearns M Untch G von Minckwitz 2006 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940 1949 10.1200/JCO.2005.02.6187 16622270 (Pubitemid 46638994)
21. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux RG Margolese JL Hoehn VG Vogel SR Dakhil D Tamkus KM King ER Pajon MJ Wright J Robert S Paik EP Mamounas N Wolmark 2008 Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols b-18 and b-27 J Clin Oncol 26 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
22. M Kaufmann G von Minckwitz HD Bear A Buzdar P McGale H Bonnefoi M Colleoni C Denkert W Eiermann R Jackesz A Makris W Miller JY Pierga V Semiglazov A Schneeweiss R Souchon V Stearns M Untch S Loibl 2007 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann Oncol 18 1927 1934 1:STN:280:DC%2BD2sjkt1KlsA%3D%3D 10.1093/annonc/mdm201 17998286 (Pubitemid 350286227)
23. MC Tan F Al Mushawah F Gao RL Aft WE Gillanders TJ Eberlein JA Margenthaler 2009 Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer Am J Surg 198 520 525 10.1016/j.amjsurg. 2009.06.004 19800460
24. M Colleoni G Viale D Zahrieh G Pruneri O Gentilini P Veronesi RD Gelber G Curigliano R Torrisi A Luini M Intra V Galimberti G Renne F Nole G Peruzzotti A Goldhirsch 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628 1:CAS:528:DC%2BD2cXot1Oiu7o%3D 10.1158/1078-0432.CCR- 04-0380 15475452 (Pubitemid 39346559)
25. C Liedtke C Mazouni KR Hess F Andre A Tordai JA Mejia WF Symmans AM Gonzalez-Angulo B Hennessy M Green M Cristofanilli GN Hortobagyi L Pusztai 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
26. Huober J (2009) Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): final results and analysis of markers predicting response to treatment. J Clin Oncol 27 (suppl, abstr 524)
27. A Rody T Karn C Solbach R Gaetje M Munnes S Kissler E Ruckhaberle GV Minckwitz S Loibl U Holtrich M Kaufmann 2007 The ERBB2 + cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GeparTrio trial Breast 16 235 240 1:STN:280:DC%2BD2szis12gsw%3D%3D 10.1016/j.breast.2007.02.006 17449250 (Pubitemid 46796861)
28. RL Jones J Salter R A'Hern A Nerurkar M Parton JS Reis-Filho IE Smith M Dowsett 2010 Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer Breast Cancer Res Treat 119 315 323 1:CAS:528:DC%2BD1MXhsFyjsL%2FF 10.1007/s10549-009-0329-x 19247830
29. E Arriola SM Rodriguez-Pinilla MB Lambros RL Jones M James K Savage IE Smith M Dowsett JS Reis-Filho 2007 Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Breast Cancer Res Treat 106 181 189 1:CAS:528:DC%2BD2sXht1CgtL7M 10.1007/s10549-006-9492-5 17260090 (Pubitemid 350045015)
30. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson KR Hess J Stec M Ayers P Wagner P Morandi C Fan I Rabiul JS Ross GN Hortobagyi L Pusztai 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 1:CAS:528: DC%2BD2MXos1Cjs7k%3D 10.1158/1078-0432.CCR-04-2421 16115903 (Pubitemid 41170290)
31. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 1:CAS:528:DC%2BD2sXkt1enur0%3D 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
32. V Guarneri K Broglio SW Kau M Cristofanilli AU Buzdar V Valero T Buchholz F Meric L Middleton GN Hortobagyi AM Gonzalez-Angulo 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 10.1200/JCO.2005.02. 6914 16505422 (Pubitemid 46638799)
33. F Andre C Mazouni C Liedtke SW Kau D Frye M Green AM Gonzalez-Angulo WF Symmans GN Hortobagyi L Pusztai 2008 HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer Breast Cancer Res Treat 108 183 190 1:CAS:528:DC%2BD1cXitleqsbs%3D 10.1007/s10549-007-9594-8 17468948 (Pubitemid 351311360)
34. A Lebeau A Turzynski S Braun W Behrhof B Fleige WD Schmitt TJ Grob L Burkhardt D Holzel C Jackisch C Thomssen V Muller M Untch 2010 Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies J Clin Oncol 28 3264 3270 10.1200/JCO.2009.25.9366 20498397